Game-Changers in Medicine: Monoclonal Antibodies Approved from 2020 to 2024

Monoclonal antibodies (mAbs) have been a focal point in therapeutic advancements over the past few years, addressing a wide range of diseases from cancer to infectious diseases like COVID-19. Here's a summary of some key monoclonal antibodies approved between 2020 and 2024:

2020

Tebentafusp: Approved for the treatment of uveal melanoma.

Faricimab: Used for the treatment of diabetic macular edema and wet age-related macular degeneration.

Mosunetuzumab: Targets B-cell non-Hodgkin lymphoma.

Teclistamab: Approved for relapsed or refractory multiple myeloma.

Mirvetuximab Soravtansine: An antibody-drug conjugate for ovarian cancer.

2021

Cadonilimab: A bispecific antibody approved in China for cervical cancer.

Ozoralizumab: Approved in Japan for rheumatoid arthritis.

2022

Bebtelovimab: Received Emergency Use Authorization for the treatment of COVID-19.

Bimekizumab: Approved for the treatment of psoriasis.

2023

Talquetamab: Targets GPRC5D and is approved for multiple myeloma.

Linvoseltamab: Another bispecific antibody approved for multiple myeloma.

Datopotamab Deruxtecan: An antibody-drug conjugate approved for non-small cell lung cancer.

Tusamitamab Ravtansine: Approved for HER2-positive breast cancer.

2024 (Forecasted)

Zanidatamab: A bispecific antibody expected to be approved for HER2-expressing cancers.

Odronextamab: Targets CD20/CD3 for B-cell malignancies.

Erfonrilimab: Expected approval for systemic lupus erythematosus.

These approvals represent a significant advancement in the field of antibody therapeutics, showcasing innovations in bispecific antibodies and antibody-drug conjugates, which enhance the targeting and treatment efficiency for various conditions, particularly cancers and immune-related disorders.

Disclaimer:

This is a personal blog. Any views or opinions represented in this blog are personal and belong solely to the blog owner and do not represent those of people, institutions or organizations that the owner may or may not be associated with in professional or personal capacity, unless explicitly stated.

Any views or opinions are not intended to malign any religion, ethnic group, club, organization, company, or individual. All content provided on this blog is for informational purposes only. The owner of this blog makes no representations as to the accuracy or completeness of any information or found by following any link.

The owner will not be liable for any errors or omissions in this information nor for the availability of this information. The owner will not be liable for any losses, injuries, or damages from the display or use of this information.

All rights reserved.